Literature DB >> 19264412

Sexual dysfunction and hormonal changes in first episode psychosis patients on olanzapine or risperidone.

Marion van Bruggen1, Thérèse van Amelsvoort, Luuk Wouters, Peter Dingemans, Lieuwe de Haan, Don Linszen.   

Abstract

Atypical antipsychotics interfere with central and peripheral neurotransmitter systems and with hormonal production. In this study we compared the effect of olanzapine and risperidone on hormonal state and sexual function (by using the Questionnaire for Sexual Dysfunction, QSD) in 40 patients with a first episode psychosis. Results were compared to those of 34 healthy controls. Patients using risperidone had significant higher prolactin levels than patients using olanzapine. Patients using olanzapine had significantly higher 17beta-estradiol levels than patients using risperidone. Overall satisfaction with sexuality was less in patients compared to controls, but not different between patients using olanzapine and those using risperidone. Problems with sexual arousal were significantly higher in patients using olanzapine compared to patients using risperidone. A significantly higher frequency of problems with ejaculation and problems with insensibility of genitals were found in patients compared to healthy controls. We found no relation between medication, prolactin and 17beta-estradiol levels, frequency of sexual activity, overall satisfaction with sexuality and any of the 18 sexual dysfunctions we investigated. Our results suggests that sexual dysfunction in patients with first episode psychosis might occur despite normal prolactin levels. Also, sexual dysfunction is highly prevalent in healthy controls. Awareness should be raised of potential sexual problems in young adults.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19264412     DOI: 10.1016/j.psyneuen.2009.01.013

Source DB:  PubMed          Journal:  Psychoneuroendocrinology        ISSN: 0306-4530            Impact factor:   4.905


  9 in total

Review 1.  The facts about sexual (Dys)function in schizophrenia: an overview of clinically relevant findings.

Authors:  Marrit K de Boer; Stynke Castelein; Durk Wiersma; Robert A Schoevers; Henderikus Knegtering
Journal:  Schizophr Bull       Date:  2015-02-25       Impact factor: 9.306

2.  Comparison of Sexual Function and Hormonal Parameters Between Mood Stabilizer Treatment Modalities in Bipolar Disorder.

Authors:  Sermin Kesebir; Burak Toprak; Burak Baykaran; Aytül Hariri; Mustafa Bilici
Journal:  Noro Psikiyatr Ars       Date:  2014-09-01       Impact factor: 1.339

3.  Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care.

Authors:  Marc DE Hert; Christoph U Correll; Julio Bobes; Marcelo Cetkovich-Bakmas; Dan Cohen; Itsuo Asai; Johan Detraux; Shiv Gautam; Hans-Jurgen Möller; David M Ndetei; John W Newcomer; Richard Uwakwe; Stefan Leucht
Journal:  World Psychiatry       Date:  2011-02       Impact factor: 49.548

4.  Translation and validation of Persian version of sexual function: vaginal changes questionnaire (SVQ) for women with gynecologic cancers.

Authors:  Raziyeh Maasoumi; Farinaz Rahimi; Somayyeh Naghizadeh
Journal:  BMC Womens Health       Date:  2022-07-08       Impact factor: 2.742

5.  Risk factors for suicide behaviors in the observational schizophrenia outpatient health outcomes (SOHO) study.

Authors:  Roberto Brugnoli; Diego Novick; Josep Maria Haro; Andrea Rossi; Marco Bortolomasi; Sonia Frediani; Giuseppe Borgherini
Journal:  BMC Psychiatry       Date:  2012-07-19       Impact factor: 3.630

Review 6.  The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review.

Authors:  J Peuskens; L Pani; J Detraux; M De Hert
Journal:  CNS Drugs       Date:  2014-05       Impact factor: 5.749

Review 7.  Management Strategies for Antipsychotic-Related Sexual Dysfunction: A Clinical Approach.

Authors:  Angel L Montejo; Rubén de Alarcón; Nieves Prieto; José Mª Acosta; Bárbara Buch; Laura Montejo
Journal:  J Clin Med       Date:  2021-01-15       Impact factor: 4.241

8.  Clinical consequences of switching from olanzapine to risperidone and vice versa in outpatients with schizophrenia: 36-month results from the Worldwide Schizophrenia Outpatients Health Outcomes (W-SOHO) study.

Authors:  Jihyung Hong; Diego Novick; Roberto Brugnoli; Jamie Karagianis; Martin Dossenbach; Josep Maria Haro
Journal:  BMC Psychiatry       Date:  2012-12-04       Impact factor: 3.630

Review 9.  Prolactin and psychopathology in schizophrenia: a literature review and reappraisal.

Authors:  Ravi Philip Rajkumar
Journal:  Schizophr Res Treatment       Date:  2014-03-27
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.